MEDFORD, Mass. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Hepregen Corporation, developer of next generation HepatoPacTM and HepatoMuneTM products, and The Hamner Institutes for Health Sciences, a nonprofit research organization focused on translational safety sciences, announced today execution of an agreement that provides for a research partnership between the two entities. The research effort will be led by Dr. Edward LeCluyse, Associate Investigator at The Hamner, and Dr. Michael Holsapple, newly appointed Vice President of Toxicology Product Development at Hepregen, along with Mr. Jack McGeehan, Hepregen’s Vice President of Operations. The partnership will focus on research and development efforts aimed at defining: (1) basic concepts regarding the potential for new micro-liver products and (2) new applications and assay methodologies for Hepregen’s existing micro-liver products that are already transforming pharmaceutical product development.

“This Hamner-Hepregen partnership brings together outstanding teams of scientists from both organizations, creating a cooperative effort that will yield new knowledge about how best to utilize Hepregen’s micro-liver products for safety testing associated with pharmaceutical and chemical product development,” stated Dr. Vincent Zurawski, Hepregen’s chief executive officer.

Dr. William Greenlee, President and CEO of The Hamner also commented, “This research partnership provides yet another example of The Hamner’s ability to attract and partner with high quality commercial enterprises that share our organization’s commitment to advancing human health. We look forward to working with Hepregen in our mutual quest to provide advanced, next generation predictive health tools to the pharmaceutical, chemical and related industries.”

About Hepregen Corporation
Hepregen Corporation is the undisputed leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and pharmaceutical, biotherapeutic and diagnostic product development. The Company’s micro-liver HepatoPacTM and HepatoMuneTM products support a potential paradigm shift in drug development. The utility of Hepregen’s human, rat, monkey and dog HepatoPacTM and HepatoMuneTM products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Venture Partners with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications. She currently chairs the Company’s scientific advisory board. For more information, visit

About The Hamner Institutes for Health Sciences
The Hamner Institutes for Health Sciences is a nonprofit translational biomedical research institute located on an open, multidisciplinary campus in North Carolina’s Research Triangle Park. Building upon 35 years of research excellence in toxicology, The Hamner works on drug and chemical safety in collaboration with academic, corporate, and government partners. Novel technologies used at The Hamner include genomic and bioinformatic approaches for improving toxicity testing, in silico models for predictive toxicology, in vitro models that utilize human cells or cell lines to evaluate perturbations of cellular responses, and in vivo models to elucidate genes that play a role in susceptibility to drug-induced toxicities. For more information, visit

Hepregen Corporation Katherine Sydney Cook, 1-781-391-0205